Details of the Drug

General Information of Drug (ID: DMLZNIQ)

• Drug Name: Sarecycline
• Synonyms: Sarecycline; UNII-94O110CX2E; 94O110CX2E; Sarecycline [USAN:INN]; Sarecycline (USAN/INN); P005672; SCHEMBL2699170; ZINC72319783; ZINC198637385; DB12035; FT-0772434; D10666

Indication

Disease Entry	ICD 11	Status	REF
Acne vulgaris	ED80	Approved	[1]

• Affected Organisms: Humans and other mammals
• ATC Code:
  J01AA14: Sarecycline
  J01AA: Tetracyclines
  J01A: TETRACYCLINES
  J01: ANTIBACTERIALS FOR SYSTEMIC USE
  J: ANTIINFECTIVES FOR SYSTEMIC USE
• #Ro5 Violations (Lipinski): 0:
  Molecular Weight (mw); 487.5
  Logarithm of the Partition Coefficient (xlogp); 1.1
  Rotatable Bond Count (rotbonds); 5
  Hydrogen Bond Donor Count (hbonddonor); 5
  Hydrogen Bond Acceptor Count (hbondacc); 10
• ADMET Property:
  Absorption Tmax: The time to maximum plasma concentration (Tmax) is 1.5-2 h []
  Clearance: The apparent oral clearance of drug is 3 L/h []
  Elimination: 42.6% of the single 100 mg dose was recovered in feces (14.9% as unchanged) and 44.1% in urine (24.7% as unchanged) []
  Half-life: The concentration or amount of drug in body reduced by one-half in 21 - 22 hours []
  Metabolism: The drug is metabolized via the enzymes in human liver microsomes []
  Vd: The volume of distribution (Vd) of drug is 91.4-97.0 L []
• Chemical Identifiers:
  Formula: C24H29N3O8
  IUPAC Name: (4S,4aS,5aR,12aR)-4-(dimethylamino)-1,10,11,12a-tetrahydroxy-7-[[methoxy(methyl)amino]methyl]-3,12-dioxo-4a,5,5a,6-tetrahydro-4H-tetracene-2-carboxamide
  Canonical SMILES: CN(C)[C@H]1[C@@H]2C[C@@H]3CC4=C(C=CC(=C4C(=C3C(=O)[C@@]2(C(=C(C1=O)C(=O)N)O)O)O)O)CN(C)OC
  InChI: InChI=1S/C24H29N3O8/c1-26(2)18-13-8-11-7-12-10(9-27(3)35-4)5-6-14(28)16(12)19(29)15(11)21(31)24(13,34)22(32)17(20(18)30)23(25)33/h5-6,11,13,18,28-29,32,34H,7-9H2,1-4H3,(H2,25,33)/t11-,13-,18-,24-/m0/s1
  InChIKey: AYUMVPHUMFKFPJ-SBAJWEJLSA-N
• Cross-matching ID:
  PubChem CID: 54681908
  CAS Number: 1035654-66-0
  UNII: 94O110CX2E
  DrugBank ID: DB12035
  TTD ID: D0T6EI
  ACDINA ID: D01411

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Bacterial 30S ribosomal RNA (Bact 30S rRNA)	TTOVFH2	NOUNIPROTAC	Inhibitor	[1]

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Disease Different from Sarecycline (Comorbidity)

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Comorbidity	REF
Gilteritinib	DMTI0ZO	Moderate	Decreased clearance of Sarecycline due to the transporter inhibition by Gilteritinib.	Acute myeloid leukaemia [2A60]	[2]
Ripretinib	DM958QB	Moderate	Decreased clearance of Sarecycline due to the transporter inhibition by Ripretinib.	Gastrointestinal stromal tumour [2B5B]	[3]
Berotralstat	DMWA2DZ	Major	Decreased clearance of Sarecycline due to the transporter inhibition by Berotralstat.	Innate/adaptive immunodeficiency [4A00]	[4]
Ubrogepant	DM749I3	Moderate	Decreased clearance of Sarecycline due to the transporter inhibition by Ubrogepant.	Migraine [8A80]	[5]
Rimegepant	DMHOAUG	Moderate	Decreased clearance of Sarecycline due to the transporter inhibition by Rimegepant.	Migraine [8A80]	[6]
Lefamulin	DME6G97	Moderate	Decreased clearance of Sarecycline due to the transporter inhibition by Lefamulin.	Pneumonia [CA40]	[7]
Betrixaban	DM2C4RF	Moderate	Decreased clearance of Sarecycline due to the transporter inhibition by Betrixaban.	Venous thromboembolism [BD72]	[8]

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG

DIG Name	DIG ID	PubChem CID	Functional Classification
Quinoline yellow WS	E00309	24671	Colorant
Sodium stearyl fumarate	E00545	23665634	lubricant
Ferric hydroxide oxide yellow	E00539	23320441	Colorant
Polyethylene glycol 4000	E00654	Not Available	Coating agent; Diluent; Ointment base; Plasticizing agent; Solvent; Suppository base; lubricant
Polyvinyl alcohol	E00666	Not Available	Coating agent; Emulsion stabilizing agent; Film/Membrane-forming agent
Povidone	E00667	Not Available	Binding agent; Coating agent; Disintegrant; Film/membrane-forming agent; Solubilizing agent; Suspending agent
Sodium bicarbonate	E00424	516892	Alkalizing agent; Diluent
Talc	E00520	16211421	Anticaking agent; Diluent; Glidant; lubricant
Titanium dioxide	E00322	26042	Coating agent; Colorant; Opacifying agent
Cellulose microcrystalline	E00698	Not Available	Adsorbent; Suspending agent; Diluent

Pharmaceutical Formulation

Formulation Name	Drug Dosage	Dosage Form	Route
Sarecycline 100 mg tablet	100 mg	Tablet	Oral
Sarecycline 150 mg tablet	150 mg	Tablet	Oral
Sarecycline 60 mg tablet	60 mg	Tablet	Oral

Jump to Detail Pharmaceutical Formulation Page of This Drug

References

• [1] Microbiological Profile of Sarecycline, a Novel Targeted Spectrum Tetracycline for the Treatment of Acne Vulgaris.Antimicrob Agents Chemother. 2018 Dec 21;63(1). pii: e01297-18.
• [2] Cerner Multum, Inc. "UK Summary of Product Characteristics.".
• [3] Cerner Multum, Inc. "Australian Product Information.".
• [4] Product Information. Orladeyo (berotralstat). BioCryst Pharmaceuticals Inc, Durham, NC.
• [5] Product Information. Ubrelvy (ubrogepant). Allergan Inc, Irvine, CA.
• [6] Product Information. Nurtec ODT (rimegepant). Biohaven Pharmaceuticals, New Haven, CT.
• [7] Product Information. Xenleta (lefamulin). Nabriva Therapeutics US, Inc., King of Prussia, PA.
• [8] Product Information. Bevyxxa (betrixaban). Portola Pharmaceuticals, South San Francisco, CA.